Related Experiment Videos
Recombinant human factor VIIa (rFVIIa) in a rabbit stasis model
V Diness1, C Bregengaard, E Erhardtsen
1Novo Nordisk A/S, Bagsvaerd, Denmark.
Thrombosis Research
|July 15, 1992
Summary
Recombinant human FVIIa (rFVIIa) showed local thrombotic effects without systemic coagulation activation. In contrast, FEIBA caused significant systemic factor consumption, indicating different safety profiles for these procoagulant agents.
Area of Science:
- Pharmacology
- Hematology
- Thrombosis Research
Background:
- Recombinant human activated factor VII (rFVIIa) and FEIBA are used to treat bleeding disorders.
- Understanding their thrombotic potential and systemic effects is crucial for patient safety.
Purpose of the Study:
- To compare the thrombogenicity of rFVIIa and FEIBA in a rabbit stasis model.
- To evaluate the systemic effects of these agents on coagulation parameters.
Main Methods:
- A rabbit stasis model was used to assess thrombus formation.
- Platelet counts, plasma fibrinogen levels, and activated partial thromboplastin time (APTT) were measured post-administration.
Main Results:
- Both rFVIIa and FEIBA induced thrombus formation during 30 minutes of stasis.
- rFVIIa showed minimal systemic effects, with no significant changes in platelet or fibrinogen levels.
- FEIBA caused dose-dependent decreases in platelet counts and fibrinogen, along with increased APTT, indicating factor consumption.
Conclusions:
- rFVIIa exhibits a local pharmacological effect with limited systemic activation of the coagulation cascade.
- FEIBA demonstrates broader systemic effects, suggesting a higher risk of general coagulation factor consumption.